Loading...
 
Mediterr J Rheumatol 2017;28(1):33-50
In vivo study of pro-inflammatory cytokine changes in serum and synovial fluid during treatment with celecoxib and etoricoxib and correlation with VAS pain change and synovial membrane penetration index in patients with inflammatory arthritis
Authors Information

1: 4th Department of Internal Medicine Hippokrateion University Hospital Aristotle University of Thessaloniki Medical School, Thessaloniki, Greece

2: Rheumatology Division, 1st Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki Medical School, Thessaloniki, Greece  

3: Forensic Medicine and Toxicology Aristotle University of Thessaloniki Medical School, Thessaloniki, Greece

4: Microbiology Dep, AHEPA University Hospital, Aristotle University of Thessaloniki Medical School, Thessaloniki, Greece
References
  1. Vane J R, Flower R J, Botting R M. History of aspirin and its mechanism of action. Stroke 1990;21:IV12-23.
  2. Niederberger E, Tegeder I, Vetter G, Schmidtko A, Schmidt H, Euchenhofer C, et al. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. FASEB J 2001;15:1622-4.
  3. Kim S H, Song S H, Kim S G, Chun K S, Lim S Y, Na H K, et al. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target. J Cancer Res Clin Oncol 2004;130:551-60.
  4. Monakier D, Mates M, Klutstein M W, Balkin J A, Rudensky B, Meerkin D, et al. Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. Chest 2004;125:1610-5.
  5. Bogaty P, Brophy J M, Noel M, Boyer L, Simard S, Bertrand F, et al. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study. Circulation 2004;110:934-9.
  6. Fort J. Celecoxib, a COX-2--specific inhibitor: the clinical data. Am J Orthop 1999;2813-8.
  7. Rainsford K D. Anti-inflammatory drugs in the 21st century. Subcell Biochem 2007;42:3-27.
  8. Chernushevich I V, Loboda A V, Thomson B A.  An introduction to quadrupole –time-of-flight mass spectrometry. J Mass Spectrom 2001;36:849-65.
  9. Wahner A D, Bronstein J M, Bordelon Y M, Ritz B. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 2007;69:1836-42.
  10. Patrignani P, Tacconelli S, Sciulli M G, Capone M L. New insights into COX-2 biology and inhibition. Brain Res Brain Res Rev 2005;48:352-9.
  11. Appleyard C B, McCafferty D M, Tigley A W, Swain M G, Wallace J L. Tumor necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence. Am J Physiol 1996;270:G42-8.
  12. Davies N M. Clinical pharmacokinetics of oxaprozin. Clin Pharmacokinet 1998;35:425-36.
  13. Edwards J C, Bowness P, Archer J R. Jekyll and Hyde: the transformation of HLA-B27. Immunol Today 2000;21:256-60.
  14. Alvarez-Soria M A, Largo R, Santillana J, Sánchez-Pernaute O, Calvo E, Hernández M, et al. Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Ann Rheum Dis 2006;65:998-1005.
  15. Du Z Y, Li X Y. Inhibitory effects of indomethacin on interleukin-1 and nitric oxide production in rat microglia in vitro. Int J Immunopharmacol 1999;21:219-25.
  16. Uzun H, Tuzun S, Ozaras N, Aydin S, Ozaras R, Dondurmaci S, et al. The effect of flurbiprofen and tiaprofenic acid on serum cytokine levels of patients with osteoarthrosis. Acta Orthop Scand 2001;72:499-502.
  17. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999;100:793-8.
  18. Ghezzi P, Melillo G, Meazza C, Sacco S, Pellegrini L, Asti C, et al. Differential contribution of R and S isomers in ketoprofen anti-inflammatory activity: role of cytokine modulation. J Pharmacol Exp Ther 1998;287:969-74.
  19. Park E M, Cho B P, Volpe B T, Cruz M O, Joh T H, Cho S. Ibuprofen protects ischemia-induced neuronal injury via up-regulating interleukin-1 receptor antagonist expression. Neuroscience 2005;132:625-31.
  20. Maneiro E, López-Armada M J, Fernández-Sueiro J L, Lema B, Galdo F, Blanco F J. Aceclofenac increases the synthesis of interleukin 1 receptor antagonist and decreases the production of nitric oxide in human articular chondrocytes. J Rheumatol 2001;28:2692-9.
  21. Yasuda O, Takemura Y, Kawamoto H, Rakugi H. Aspirin: recent developments. Cell Mol Life Sci. 2008;65:354-8.
  22. Bianchi M, Broggini M, Balzarini P, Franchi S, Sacerdote P. Effects of nimesulide on pain and on synovial fluid concentrations of substance P, interleukin-6 and interleukin-8 in patients with knee osteoarthritis: comparison with celecoxib. Int J Clin Pract 2007;61:1270-7.
  23. Kang B S, Chung E Y, Yun Y P, Lee M K, Lee Y R, Lee K S, et al. Inhibitory effects of anti-inflammatory drugs on interleukin-6 bioactivity. Biol Pharm Bull 2001;24:701-3.
  24. Schumacher H R Jr, Meng Z, Sieck M, Zonay L, Clayburne G, Baker J F, et al. Effect of a non-steroidal anti-inflammatory drug on synovial fluid in osteoarthritis. J Rheumatol 1996;23:1774-7.
  25. Bresee C J, Delrahim K, Maddux R E, Dolnak D, Ahmadpour O, Rapaport M H. The effects of celecoxib augmentation on cytokine levels in schizophrenia. Int J Neuropsychopharmacol 2006;9:343-8.
  26. Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther 2003;74:130-7.
  27. Sönmez K, Karabulut R, Türkyilmaz Z, Demiroğullari B, Ozen I O, Gülen S, et al. Association of tumor necrosis factor, interleukin-6 and cyclooxygenase pathway with lipopolysaccharide-induced intussusception. Eur J Pediatr Surg 2008;18:103-6.
  28. Ochalski S J, Hartman D A, Belfast M T, Walter T L, Glaser K B, Carlson R P. Inhibition of endotoxin-induced hypothermia and serum TNF-alpha levels in CD-1 mice by various pharmacological agents. Agents Action 1993;39 Spec No:C52-4.
  29. Cazanave S, Vadrot N, Tinel M, Berson A, Lettéron P, Larosche I, et al. Ibuprofen administration attenuates serum TNF-alpha levels, hepatic glutathione depletion, hepatic apoptosis and mouse mortality after Fas stimulation. Toxicol Appl Pharmacol 2008;231:336-43.
  30. Murakami N, Aihara S, Iwata K, Saito T, Naruse T. Effect of a novel non-steroidal anti-inflammatory drug (M-5011) on cytokine levels in rats with monosodium urate crystal- induced pleurisy. Jpn J Pharmacol 1999;79:439-46.
  31. Peter Brooks: Non-steroidal anti-inflammatory drugs. Volume 1, section 4, pg 377, Rheumatology, Third edition. London:Mosby;2003.
  32. Scott G, Rordorf C, Reynolds C, Kalbag J, Looby M, Milosavljev S, et al. Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet 2004;43:467-78.
  33. Netter P, Bannwarth B, Royer-Morrot M J. Recent findings on the pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet 1989;17:145-62.
  34. Day R O, McLachlan A J, Graham G G, Williams K M. Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet 1999;36:191-210.
  35. Dromgoole S H, Furst D E, Desiraju R K, Nayak R K, Kirschenbaum M A, Paulus H E. Tolmetin kinetics and synovial fluid prostaglandin E levels in rheumatoid arthritis. Clin Pharmacol Ther 1982;32:371-7.